Brief: Matinas Biopharma Holdings Q2 Loss Per Share $0.03
13/08/2019 12:37
Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA REPORTS SECOND QUARTER 2019 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* Q2 LOSS PER SHARE $0.03
* Q2 EARNINGS PER SHARE ESTIMATE $-0.04 -- REFINITIV IBES
DATA
* ADDITIONAL HEAD TO HEAD DATA VERSUS. VASCEPA® EXPECTED IN
2020
* MATINAS BIOPHARMA HOLDINGS - CASH AND CASH EQUIVALENTS AT
JUNE
30, 2019 WERE APPROXIMATELY $36.8 MILLION, COMPARED TO $12.4
MILLION AT DECEMBER 31, 2018
* NIH-FUNDED PHASE 1/2 ENACT TRIAL OF MAT2203 IN
CRYPTOCOCCAL
MENINGITIS TO COMMENCE IN Q4 2019
* ON TRACK TO COMMENCE A COMPARATIVE CLINICAL BRIDGING
BIOAVAILABILITY STUDY IN Q4 2019, EXPECTED COMPLETION IN Q1 2020
Source text for Eikon: ID:nGNX3wsYyr
Further company coverage: MTNB.A
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing